HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $31 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Matthew Keller reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $31 price target.
HC Wainwright & Co. analyst Matthew Keller reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $31 price target.